# K063101: Microscan Microstrep Plus Panel Cefotaxime (0.015 - 8 MCG/ML

- Pathway: 510(k) (Traditional)
- Applicant: Dade Behring, Inc.
- Decided: Nov 1, 2006 after 22 days
- Product code: LRG (Instrument For Auto Reader & Interpretation Of Overnight Suscept. Systems)
- Device class: 2
- Regulation: 21 CFR 866.1640
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 2 generations back to K963641 (1996). 2 ancestors in all.
No later device cites it as a predicate yet.
0 of 3 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K021111: Microscan Microstrep Plus Panel New Antimicrobial - Cefotaxime, Dade Microscan, Inc. (2002)

## Indications for use
The MicroScan MICroSTREP plus Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20 - 24 hours at 35 0 C +/- iC in a non-CO2 incubator, and read visually according to the Package Insert. Additionally, the panels may be incubated in and read by a MicroScan WalkAway instrument. This particular submission is for the addition of instrument read capability of the antimicrobial Cefotaxime, at concentrations of 0.015 - 8 mcg/ml on the MicroScan MIICroSTREP plus® Panel. The organisms which may be used for Cefotaxime susceptibility testing in this panel are: Streptococcus pneumoniae Streptococcus pyogenes (Group A beta-hemolytic streptococci) Streptococcus spp.

Source page: https://510kreport.com/device/K063101
Methodology: https://510kreport.com/methodology